Results 21 to 30 of about 681,456 (227)
The Korean Journal of Gastroenterology, 2019 Background/Aims: Current knowledge and viewpoints regarding biosimilars among physicians in Asia are unknown, even though these were investigated by European Crohn’s and Colitis Organization (ECCO) members in 2013 and 2015.
Soo-Kyung Park +4 more
doaj +1 more source
Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain
Pharmaceuticals, 2021 Incentives contribute to the proper functioning of the broader contracts that regulate the relationships between health systems and professionals.
F. Lobo, Isabel Río‐Álvarez
semanticscholar +1 more source
Journal of Pharmaceutical Health Care and Sciences, 2019 Background Infliximab (IFX) has changed the management of many life-threatening immune-mediated diseases. The high cost of IFX and its patent expiry have led to pharmaceutical companies developing a biosimilar; however, its safety profile remains unknown
Iku Niinomi +6 more
doaj +1 more source
Generics, Biosimilars, and the Ethics of Pricing Pharmaceuticals [PDF]
Journal of Veterinary Science & Medicine, 2016 Recent price hikes by pharmaceutical companies underscore the importance of competition in an industry that often sets prices according to what the market will bear. A steady pipeline of generics and biosimilars is the surest check to the rising prices of drugs and biologics.
openaire +1 more source
Frontiers in Pharmacology, 2022 Background: The level of competition achieved following biosimilars market availability varies by country, care setting and molecule. Hence, biosimilars contribution to attaining price reductions and extended access to treatments can also vary. Objective:
Teresa Barcina Lacosta +3 more
semanticscholar +1 more source
BMC Health Services Research, 2022 Background In Norway, an annual tender system for the prescription of biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) has been used since 2007. This study aimed to explore annual b/tsDMARDs costs and disease outcomes in
Alen Brkic +10 more
doaj +1 more source
Generic Medicines and Biosimilars: Impact on Global Pharmaceutical Policy
, 2020 Patient access to safe and cost-effective treatment is an important goal for the healthcare system. The development of biosimilar compounds and generic medicines is interesting to the industry and society to reduce healthcare costs, fulfill the needs of healthcare stakeholders and potentially increase accessibility to patients.
Ibrahim, Mohamed Izham Mohamed +1 more
openaire +3 more sources
Ophthalmology and Therapy, 2021 Ranibizumab is approved for the treatment of several macular disorders, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) and myopic choroidal neovascularization (mCNV), among others. The
Shashikant Sharma +4 more
semanticscholar +1 more source
Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS [PDF]
Current Pharmaceutical Biotechnology, 2016 Therapeutic monoclonal antibodies (mAbs) have made a tremendous impact in treating patients with various diseases. MAbs are designed to specifically target a cell and illicit a response from the immune system to destroy the cell. As originator mAb drug patents are coming to an end, generic pharmaceutical companies are poised to replicate and produce so-
Kerry M, Wooding +2 more
openaire +2 more sources
Pharmaceuticals, 2021 This study aimed to compare drug costs and healthcare costs of a 1 year adjuvant course with intravenous biosimilar trastuzumab vs. subcutaneous reference trastuzumab in HER2-positive breast cancer from the Belgian hospital perspective. Our simulation is
S. Simoens, A. Vulto, P. Dylst
semanticscholar +1 more source